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Available online 19 October 2016Tumor necrosis factor (TNF) is a key cytokine in HIV replication and pathogenesis. For reasons that are not
entirely clear, the cytokine remains upregulated despite anti-retroviral therapy (ART). Here we demonstrate
that HIV Nef induces an alternative TNF secretion mechanism that remains active in chronic infection. Ingestion
of Nef-containing plasma extracellular vesicles (pEV) from ART patients by primary immune cells, but also Nef
expression, induced intracellular proTNF cleavage and secretion of vesicular TNF endosomes. Key event was
the Nef-mediated routing of the TNF-converting enzyme ADAM17 into Rab4+ early endosomes and the
Rab27+ secretory pathway. Analysis of lymph-node tissue by multi-epitope-ligand-cartography (MELC) con-
ﬁrmed a vesicular TNF secretion phenotype that co-localized with persistent Nef expression, and implicated
Notch1 as an essential co-factor. Surprisingly Notch1 had no transcriptional effect but was required for the
endosomal trafﬁcking of ADAM17. We conclude that Nef expression and Nef-containing pEV mobilize TNF
from endosomal compartments in acute and chronic infection.
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Notch11. Introduction
Early in HIV research it was demonstrated that pro-inﬂammatory
cytokines, in particular TNF, drive HIV replication and pathogenesis
(Reddy et al., 1988; Fauci, 1996). However, despite efﬁcient ART, TNF
plasma levels remain elevated and soluble forms of the TNF receptors
(TNFR-I and II) even increase (Aukrust et al., 1999; Wada et al., 2015).
As both, proTNF cleavage and TNFR shedding, require the activation of
TNF-alpha converting enzyme (TACE/ADAM17), the activation of this
protease seems at least in part unaffected by ART. Reafﬁrming a role of
TNF in chronic HIV infection, treatment with TNF inhibitors improves
CD4 counts and reduces immune activation (Gallitano et al., 2016;
Kumar et al., 2013).
To explain chronic immune activation, it is suggested that direct and
indirect effects of the infection, as for example microbial translocation,
viral co-infections and HIV expression itself including exosomal TAR
RNA, stimulate the innate immune sensing system leading to immune
cell stimulation and TNF production (Sandler and Douek, 2012;
Iwasaki, 2012; Lawn, 2004; Sampey et al., 2016). In addition a direct
stimulation of cytokine production has been reported for Vpr, Tat andur).
. This is an open access article underNef, however, most of these studies were done with recombinant viral
proteins (Kumar et al., 2013).
Since viral replication is greatly reduced in chronic infection, current
concepts do not consider a major role of viral proteins in persistent im-
mune activation. This includes the viral Nef protein, an essential cofac-
tor of HIV replication in vivo (Gorry et al., 2007). Therefore, the role of
Nef appears to be restricted to augment viral replication in a yet poorly
understoodmanner that seems to include receptor trafﬁcking and stim-
ulation of T cell signaling (Abraham and Fackler, 2012; Baur, 2011).
We have previously reported that Nef activates and shuttles activat-
ed ADAM17 into extracellular vesicles (EV) (Lee et al., 2013). This oc-
curred through interaction with a multifaceted protein complex
termed the Nef-associated kinase complex (NAKC). In more recent re-
sults we demonstrated that Nef/ADAM17-containing plasma extracel-
lular vesicles (HIV-pEV) persist in high concentrations despite ART
and correlate with low CD4 counts (Lee et al., 2016). Together these
ﬁndings suggested that Nef has a direct role in HIV immune activation
and in AIDS pathogenesis. To substantiate this assumption we were
looking for amechanistic link between the effects of Nef andHIV plasma
EV (pEV) and the release of TNF in chronic infection.
To this end we analyzed TNF secretion in vitro and in/with human
material from ART patients. In addition to current concepts, which de-
scribe a plasma membrane (PM)-associated shedding of soluble TNF,
we found that the larger pool of proTNF is cleaved intracellularly andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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quired the translocation of ADAM17 into Rab4+ compartments,
where the protease convergedwith its substrate. Analysis of human tis-
sue conﬁrmed these ﬁndings and implicated Notch1 as a crucial co-fac-
tor in trafﬁcking of ADAM17. We conclude that HIV evolved a powerful
TNF-mobilizing mechanism, which persists in ART-patients and may
contribute to chronic immune activation.
2. Material and Methods
2.1. Cell Lines, Antibodies, Reagents and Plasmids
293Tcells were cultured in DMEM (Lonza), 10% (v/v) fetal bovine
serum (FBS)with Penicillin-Streptomycin (P/S) at 37 °C, 5% CO2. follow-
ing antibodies and reagents were purchased: α-Nef (JR6) and α-
ADAM17 (Abcam); α-mouse Alexa555 (Life Technologies); TAPI-1
(Life Technologies); PMA (Sigma Aldrich); BrefeldinA andWortmannin
(Becton Dickinson); GMCSF (Miltenyi Biotech); Ly294002 (Selleck
Chemicals); YO-01027 (Cellagen Technology). Plasmids for ADAM17,
GFP-proTNF-RFP and HIV NL4-3 with SF2 nef and NL4.3 delta nef were
described recently (Fackler et al., 2006). The PI3-kinase regulatory do-
main p85 was described in (Wolf et al., 2001). Rab-GFP (4, 11, 27a
and 27b), RFP-ADAM17, TNFalpha-RFP and fusion proteins were con-
structed by overlapping PCR-based cloning technique. The Nef mutants
Nef.LL/AA and Nef.ED/AA and were obtained from Warner Greene
(Bresnahan et al., 1998) andMatija Peterlin (Lu et al., 1998) respective-
ly. For the MELC analysis the following antibodies were used: CD4
(13B8.2, Beckman Coulter); ADAM10 (SHM14, Biolegend, PE); TNFα
(D1G2; Cell Signaling, FITC); CD107a (H4A3 FITC, BD Pharmingen);
CD45 (5B1 FITC, Miltenyi); HLA DR (Immu-357 FITC, Beckman Coulter);
HLA ABC (B9.12.1 FITC, Beckman Coulter); Notch1 (527425 PE,
BioLegend); Propidium iodide (Genaxxon). Anti-Nef and anti-gag p24
(both sheep polyclonal) were provided by NEXT Biomed, Helsinki.
2.2. Transfections and Protein Assays
Transient transfections into 293T cells were performed as described
previously (Wolf et al., 2008) and harvested/analyzed usually 24–36 h
after transfection. Macrophages (4 × 104 cells/well) were seeded on
glass slides in a 12well plate in 800 μl RPMI substituted with 1%
human serum, P/S and 800 U/ml GMCSF. After adherence, cells were
transfected using the FuGene HD reagent (Promega, Mannheim,
Germany) according to manufacturer's protocol.
For pulse chase analysis of ADAM17, 12×105 293T cellswere seeded
onto glass slides in a 12 well dish and transfected with ADAM17 and
Rab27a or Rab27b. 16 h after transfection cells were gently washed
and incubated with PBS at 4 °C. After 10 min a non-conjugated α-
ADAM17 (mouse) antibody was added and incubated for 30 min at
4 °C. Subsequently cells were gently washed and either incubated
with media containing PMA, PMA and Monensin or PMA and Brefeldin
A for another 30 min at 4 or 37 °C. Finally, cells were ﬁxed for 30 min
with 4% PFA and stained with a secondary antibody (goat α-mouse).
ADAM activity in EV was measured using the SensoLyte®520
ADAM17 (α-Secretase) Activity Assay Kit from AnaSpec according to
themanufacturer's procedures. Plasma-derived EV (pEV) were puriﬁed
as described below and 10 μl of a pEV-containing PBS solution, corre-
sponding to 1 ml plasma, were used according to the manufacturers
procedures.
To assess TNF secretion from PBMC, cells (1 × 105) were placed in
96-well-U-bottom plates in a total volume of 100 μl (RPMI) and 10 ng
of p24 (10 μl) or 10 μl EV corresponding to 1ml plasmawere incubated.
When indicated, 10 μl PHA (positive control) or 50 μMTAPI-1 (Peptides
International), were used. TNF in the supernatant (100 μl) was mea-
sured after 16 h using the CBA (Cytometric Bead Array) Human Soluble
Protein Flex Set System (BD Biosciences).2.3. Plasmid Microinjection
Primary human macrophages were grown on cover glasses and
microinjected into their nuclei with an AIS 2 microinjection apparatus
using pulled borosilicate glass capillaries in principle as reported
(Schmidt et al., 2011). Plasmid encoding Nef wt or pcDNA3.1(+) as
control and the G-proTNF-R indicator plasmid were mixed in water at
concentrations of 10 ng/μl. Dibenzazepine (YO-01027), or DMSO as con-
trol, was added approx. 1,5 h before microinjection. Following microin-
jection, cells were cultured for 6 h to allow protein expression. At the
indicated time point cells were ﬁxed with PBS 4% paraformaldehyde
and subjected to microscopic analysis.
2.4. Isolation and Puriﬁcation of pEV
Plasma EV puriﬁcation was performed as previously described
(Muratori et al., 2009). Brieﬂy, 12 ml blood plasma was diluted with
12 ml PBS and centrifuged for 30 min at 2000 g, 45 min at 12,000g
and ultra-centrifuged for 2 h at 110,000g. Pellets were washed in
32 ml PBS and pEV were ultra-centrifuged for 1 h at 110,0007g. Pellets
were resuspended in a ﬁnal volume of 120 μl, resulting in an equivalent
of 1 ml plasma in 10 μl pEV-suspension.
2.5. Patients, Tissue and Primary Cells
Blood was drawn from patients and healthy donors after an in-
formed consent, approved by the local ethics committee, was signed.
At the time of blood sampling, all HIV-1 patients were under HAART
treatment, showing no detectable levels of viral load (below 20
copies/ml blood). The axillary lymph nodes were obtained (04/2008)
from a 42 year old male HIV patient treated since 2005, suppressing
his viral load to non-detectable levels. Despite treatment, his CD4
count dropped in 2007/8 to 200–300 helper T cells/μl and he developed
non-viremic AIDS and died in 2008.
For isolation of PBMCs, EDTA blood samples were diluted 1:1
with PBS and loaded on a 15 ml cushion of Lymphoprep (Axis
Shield, Heidelberg, Germany) and centrifuged at 1.500 rpm for
30 min. The obtained cell layers were diluted in cold PBS, spun down
at 1150 rpm/4 °C andwashed 2-timeswith PBS. For the Cytokine release
assays (Fig. 1b), cells were suspended in RPMI 10% FCS in a concentra-
tion of 1 × 106 PBMC/ml. For the generation of macrophages, PBMC
were seeded in a density of 15 × 107 cells/20 ml RPMI for 1 h in a
T175 ﬂask. After adherence, cells were thoroughly washed and, over a
2 weeks period, repeatedly supplied with fresh RPMI containing 1%
human sera and 800 U/ml GMCSF.
2.6. Immunoﬂuorescence and Confocal Microscopy
Immunostainings were performed as described previously
(Muratori et al., 2009). Slides were analyzed either on LEICA TCS SP5
laser scanning microscope equipped with the LAS-AF software (Leica
Microsystems,Mannheim,Germany) and, due to the purchase of anoth-
er system, on a Zeiss Laser ScanningMicroscope LSM780 equippedwith
the ZEN software (Carl Zeiss AG, Oberkochen, Germany).
2.7. MELC Technology
TheMELC technology has been described previously (Schubert et al.,
2006; Baur et al., 2013). Brieﬂy, a slide with two tissue specimens were
placed side by side on an inverted wide-ﬁeld ﬂuorescence microscope
(Leica) ﬁtted with ﬂuorescence ﬁlters for FITC and PE. Fluorochrome
conjugated antibodies and wash solutions were added to both samples
simultaneously and removed robotically under temperature control,
avoiding any displacement of the samples and objective. In each stain-
ing cycle, an antibody was added; phase contrast and ﬂuorescence im-
ages were recorded by a high-sensitivity cooled CCD camera; the
Fig. 1.HIV pEV induce endosomal proTNF cleavage. (a) HIV pEV from ART patients induce TNF secretion in PBMC. Resting PBMC were incubated with puriﬁed pEV (equivalent to 1 ml of
plasma) for 12 h w/wo TAPI-1 before culture supernatants were assayed for TNF by CBA (pg/ml). H1–H5: HIV patients 1–5. C1–3: healthy controls 1–3. One PBMC aliquot was stimulated
with PHA. For control, input aliquots of HIV patients (Hv) and healthy control (Co) were pooled and analyzed for TNF. Error bars were calculated on the basis of triplicates of a single
experiment, performed 3 times with different donor PBMC. (b) Induction of proTNF cleaving EV is Nef-dependent. EV were puriﬁed from 293 T cell culture supernatants transfected
with CN (CD8.Nef), CN.11-40, Tat, Vpr or Vpu and incubated with PBMC and analyzed as in (A). Error bars indicate standard deviation of the mean from three transfections. (c) Nef-
induced EV obtain their proTNF cleaving ability in the produced cell. Same experimental setup as in (b) transfecting CN; however in one aliquot the EV-producing cells were incubated
with TAPI, in another aliquot the target PBMC. (d) Spatial orientation of G-pTNF-R in endosomes. 293 T cells were transfected with G-pTNF-R and analyzed by confocal microscopy
after 24 h. (e) HIV pEV induce a vesicular secretion mechanism. G-pTNF-R transfected 293T cells (12 h) were incubated with HIV pEV (1 ml plasma equivalent pooled from different
donors) for 8 h, mixed with non-transfected cells (1:4; 12 h) and analyzed by confocal microscopy. (f) HIV pEV induce proTNF cleavage in macrophages. Macrophages were incubated
(16 h) with pEV-aliquots as in (a) before yellow (proTNF) and red (mature TNF) vesicular compartments were quantiﬁed in % of total vesicles, counted on one confocal level
(examples at the bottom) of 20 randomly selected cells for each condition. Error bars indicate standard deviation of the mean of 20 cells. (g) HIV pEV induce TNF release in the not-
adherent PBMC fraction (NAF: T/B cells). PBMC and the NAF fraction of the same PBMC were incubated with HIV pEV as in (a). In addition, cells were stained for TNF by confocal
microscopy as indicated. Error bars were calculated on the basis of triplicates.
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lengths. Data acquisition was fully automated.2.8. HIV Replication in PBMCs
Peripheral bloodmononuclear cells (PBMCs) fromhealthy blood do-
nors were puriﬁed by Ficoll-Hypaque gradient centrifugation. 2 × 106
cells were plated in 200 μl medium without stimuli per well in 96well
V-bottom plates. HIV-1NL4.3 SF2 nef (Wt) or HIV-1 NL4.3Δnef
(Fackler et al., 2006) virus was concentrated using Centricon® Plus-70
spin columns (Millipore, Billerica, MA) from the supernatant of infected
MT-4 cells and used for infection (10 ng or 100 ng p24 per well). After
wash-out of input virus 3 h post infection, cultures were kept in the
presence of solvent control or 10 ng/μl YO-01027 and the cell culture su-
pernatant was analyzed for TNF content by CBA (24 h p.i.) or HIVreverse transcription activity by the SG-PERT assay (over 16 days p.i.)
(Trotard et al., 2016).
2.9. Image Quantiﬁcations of Immunoblotting
All image quantiﬁcations were performed with ImageJ software
(NIH). The quantiﬁed data were analyzed using Excel 2010 (Microsoft)
for statistical analysis.
2.10. Statistical Analyses
Selected signiﬁcance analyses in bar diagrams show the means and
standard deviations for 3 independent experiments. Statistical compar-
ison was performed using the student t-test or Mann-Whitney U tests
(SPSS Inc.; Chicago; USA). The level of signiﬁcance was set at p b 0.05.
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3.1. Plasma Extracellular Vesicles (pEV) from HIV ART Patients Induce TNF
Cleavage in Endosomes
Plasma EV from HIV ART patients contain Nef and TNF converting
enzyme (TACE/ADAM17) (Lee et al., 2016). We asked whether and
how these vesicles would induce TNF cleavage and release in target
cells. Vesicles were puriﬁed from 5 HIV-infected individuals under
ART with no plasma viral load and 3 healthy controls. Aliquots equiva-
lent to 1 ml plasma containing Nef and ADAM17 (Fig. S1a) were incu-
bated with resting PBMC. After 12 h TNF was detected in all HIV pEV/
PBMC incubations but not in controls (Fig. 1a). TNF secretion was
blocked by the addition of TAPI-1, an established ADAM17 inhibitor.
ProTNF cleavage was Nef-dependent as puriﬁed EV from transfected
293T cells revealed that only Nef (represented by a CD8.Nef (CN) fusion
protein), but not Tat, Vpr or Vpu induced EVwith the capacity to cleave
proTNF in target PBMC (Fig. 1b). Similarly, a CD8.Nef mutant (CN.11-
40), unable to interact with the Nef-associated kinase complex
(NAKC) and stimulate secretion (Muratori et al., 2009), failed to induce
EV with proTNF cleavage ability (Fig. 1b). Preincubation of EV producer
cells (293T), but not target cells (PBMC), with TAPI-1 abolished proTNF
cleavage, implying that the processing protease originated from the EV
producing cell (Fig. 1c). Consistent with this result, aliquots of the HIV
pEV samples revealed strong ADAM17 activity as assessed by a com-
mercial assay (SensoLyte®, AnaSpec) (Fig. S1b), which correlated with
the presence ADAM17 protein (Fig. S1c).
Since resting PBMC have little to none proTNF on their cell surface,
we asked whether TNF was secreted from an intracellular compart-
ment. To test this assumption we transfected 293T cells with an indica-
tor plasmid for proTNF cleavage (GFP-proTNF-RFP or G-pTNF-R). The
fusion protein, which is expressed at the plasma membrane and in
endosomes (see Fig. 4c) gives a yellow color under UV light, whereas
its cleavage produces a red (TNF-RFP) and green moiety (GFP-pro)
(Lee et al., 2013). The C-terminal TNF part (red) of endosomal G-
proTNF-R was directed towards the lumen, while the pro-domain
(green) was anchored in the membrane (Fig. 1d, arrows). Incubation
of individual HIV pEV samples (1 ml plasma-equivalent) with G-pTNF-
R-transfected cells induced an intracellular TNF cleavage, evidenced by
the appearance of red (TNF-RFP) and disappearance of yellow vesicles
(Fig. S1d). Strikingly, these TNF-RFP containing vesicular structures
were transferred to non-transfected bystander cells (Fig. 1e, white ar-
rows). A similar result was obtained when G-pTNF-R-transfected mac-
rophages were incubated with HIV-pEV (Fig. 1f). Also Macrophages
seemingly secreted the red TNF vesicles, suggested by the strong de-
crease of their relative number per cell. Comparable TNF secretion was
observed when the PBMC non-adherent fraction (NAF; mainly T and B
cells) were incubated with HIV pEV, showing that not only monocyte-
derived cells secreted TNF (Fig. 1g, see also Fig. 5). Taken together,
pEV from HIV-patients under ART had a strong capacity to induce
proTNF cleavage in endosomes, leading to an unusual vesicular secre-
tion mechanism.
3.2. PMA, Nef and HIV pEV Trigger TNF Trafﬁcking into Rab4+ and
Rab27+ Compartments
To detail this mechanism, we analyzed the trafﬁcking of a TNF-RFP
fusion protein in 293T cells using a panel of Rab-GFP proteins (Fig.
S2). The transfected cells were stimulated with PMA, by expression of
Nef and Nef cofactors (Nef-associated kinase complex (NAKC), see
(Lee et al., 2013)) or by incubation with HIV pEV from ART patients.
Without stimulation (PBS) TNF-RFP was only seen in Rab4+ early
endosomes (EE), likely translocating from the Golgi (Stenmark, 2009)
(Fig. 2a, quantiﬁcation by bar diagram). Upon PMA stimulation or ex-
pression of Nef/NAKC, TNF-RFP appeared in Rab4/Rab5+ compart-
ments (likely Rab4/Rab5 double positive EE) and in Rab27a/b+secretory vesicles (Fig. 2a, white arrows). This suggested two possible
TNF secretion routes, namely from the ER/TGN directly into the secre-
tion pathway (Fig. 2a, cartoon, route A), or through Rab4+ compart-
ments (route B). In contrast to some cell surface receptors that are
downregulated by Nef (Chaudhry et al., 2008; Madrid et al., 2005),
TNF was not seen in Rab11+ recycling endosomes (RE). However,
some of the cytokine appeared in Rab7+ late endosomes (LE) or lyso-
somes, where Nef and associated receptors were also found (Schaefer
et al., 2008). Monensin or Brefeldin A blocked or reduced the appear-
ance of TNF-RFP in Rab4+ and Rab27+ endosomes (Fig. S3),
conﬁrming that TNF-RFP was trafﬁcking through the Golgi/TGN to EE
as suggested previously (Stow and Murray, 2013).
HIV pEV incubation with target cells induced a similar effect as ex-
pression of Nef/NAKC, and TNF-RFPwas shuttled into Rab27+ secretion
compartments (Fig. 2b, white arrow, red bars). Under these conditions a
considerable amount of TNF was also found in late endosomes
(Rab7+). Taken together, PMA, Nef/NAKC and HIV pEV induced a sim-
ilar routing and secretion of TNF.
3.3. HIV pEV andNef/NAKC Shuttle ADAM17 into Rab4+Compartments for
proTNF Cleavage
Next we asked where endosomal proTNF was cleaved by ADAM17.
Under non-stimulated conditions (PBS), an ADAM17-RFP fusion-pro-
tein was not detected in any of the compartments labelled by the
transfected Rab proteins (Fig. 3a). Conversely, upon Nef/NAKC expres-
sion a strong, often doughnut-shaped (see inserts) colocalization of
ADAM17 with Rab5, Rab4 and Rab27a/b was seen, implying that the
protease was shuttled into the secretory pathway via Rab4+ EE
(Fig. 3a).
Monensin and Brefeldin A did not inhibit the routing of ADAM17
(Fig. 3a, lower panels), suggesting that the protease was shuttled from
the PM into Rab4+ EE but not from the ER/Golgi (see cartoon). For con-
ﬁrmation we performed a pulse chase experiment. Surface ADAM17
was pulsed and chased at 37 °C for 30 min in the presence of PMA. In-
deed, ADAM17 colocalized with Rab27a/b and this was not inhibited
by Monensin or Brefeldin A (Fig. 3b). We also detected budding struc-
tures containing ADAM17 that resembled the EV-clusters described in
our previous report (see arrows in lower right panels) (Muratori et al.,
2009).
Upon incubation of HIV pEV with target cells similar doughnut-
shaped Rab4 and Rab27 colocalizations were observed as with Nef/
NAKC expression (Fig. 3c). The strong effect implied that HIV pEV in-
duced endosomal circulation of ADAM17. These data also suggested
that activated ADAM17 convergedwith proTNF in EE, placing TNF in se-
cretion route B (see cartoon in Fig. 2a).
3.4. TNF and ADAM17 Converge in Early Endosomes for Intracellular
proTNF Cleavage and Secretion
To conﬁrm the last conclusion, ADAM17, TNF-RFP, Rab4-GFP and
Nef/NAKC were co-expressed. After 24 h we observed an onion layer-
like colocalization of ADAM17, Rab4 and TNF in EE, but only in presence
of Nef/NAKC (Fig. 4a, lower panels). We then asked whether the shut-
tling of ADAM17 required the interaction of Nef with the endocytosis
machinery. Two Nef mutants were analyzed that disrupt interactions
of Nef with the adaptor protein complexes and the vacuolar ATPase
(Nef.LL/AA and ED/AA) (Bresnahan et al., 1998; Lu et al., 1998), of
which Nef.ED/AA is also defective for assembly of NAKC (Witte et al.,
2004).
As expected, both mutants blocked the internalization of Nef by
preventing the formation of Nef-containing clathrin coated vesicles
(CCV) (Fig. S4). In addition, the secretion of TNF was halted at the
level of the Rab4+ EE (Fig. 4b). This was likely due to the blocked traf-
ﬁcking of ADAM17, as both Nef mutants inhibited the internalization of
the protease (Fig. 4b).
Fig. 2. PMA, Nef/NAKC and HIV pEV shuttle TNF from Rab4+ EE into the p27+ secretory pathway. (a) TNF is constitutively present in Rab4+ EE and mobilized by PMA or Nef/NAKC
(NAKC: PKCδ, hnRNPK, Lck) into Rab27+ secretory compartments. TNF-RFP and Rab-GFP transfected 293T cells were stimulated with PMA, or co-transfected with Nef/NAKC and
analyzed for TNF/Rab colocalization by confocal imaging. Representative images are shown for each condition. The positive phenotype (TNF/Rab colocalization) was quantiﬁed (bar
diagrams) in % of 15 transfected and randomly selected cells in three independent experiments. Error bars indicate standard deviation of the mean from three transfections. The
cartoon depicts the two possible secretion routs (red arrows, a and b) of TNF under stimulating conditions (PMA or Nef/NAKC). (b) HIV pEV shuttle TNF into the secretion pathway.
TNF-RFP and Rab-GFP proteins were cotransfected into 293T cells and incubated with puriﬁed HIV and control pEV-aliquots (1 ml plasma equivalent, as in 1D) for 16 h before being
analyzed for TNF/Rab colocalization. Analysis and quantiﬁcation of the phenotype (TNF/Rab co-localization) as in (a).
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generally assumed that the cytokine is shuttled via the Rab11+
recycling endosomes (RE) to the cell surface to be cleaved by ADAM17
(StowandMurray, 2013). For clariﬁcationwe analyzed proTNF cleavage
and secretion using PMA stimulation. Expression of G-pTNF-R in 293T
cells revealed two distinct proTNF pools, namely at the PM and the
perinuclear region (ER/Golgi) (Fig. 4c-1). Five minutes after PMAstimulation the PM pool was processed, leaving behind the GFP-pro
(green) cleavage product (Fig. 4c-2). In the remaining perinuclear
pool, proTNF cleavage started after 10 min, visible by the intracellular
appearance of red vesicles perpendicular around yellow endosomal
compartments (Fig. 4c-3). The process was completed after 20 min
leaving behind only red vesicles with mature TNF-RFP transported
to the periphery of the cell (Fig. 4c-4). Together these data
Fig. 3. PMA, Nef/NAKC and HIV pEV shuttle ADAM17 from the PM into secretory pathway. (a) ADAM17 is mobilized by Nef/NAKC into Rab4+ EE and Rab27+ secretory compartments.
ADAM17-RFP and Rab-GFP proteinswere cotransfectedw/woNef/NAKCandanalyzed for ADAM17/Rab colocalization (upper two image panels). In addition,Nef/NAKC cotransfected cells
were stimulated with Brefeldin A or Monensin (lower two image panels). The cartoon depicts the secretion rout of ADAM17 upon Nef/NAKC expression and Monensin and Brefeldin A
treatment. Analysis and quantiﬁcation (bar diagram) of the phenotype (ADAM17/Rab co-localization) as in Fig. 2. (b) PMA-activated ADAM17 is shuttled from the PM into Rab4+ EE
and the Rab27+ secretory pathway. Pulse/chase of ADAM17 cotransfected with Rab27b. After 16 h a non-conjugated α-ADAM17 antibody was added (pulse) and chased for 30 min
either in the presence of PMA, PMA and Monensin or PMA and Brefeldin A as indicated. Then cells were stained with a conjugated secondary antibody and analyzed for ADAM17/Rab
colocalization. (c) HIV pEV shuttle ADAM17 into the secretion pathway. ADAM17-RFP and Rab-GFP proteins were co-transfected into 293T cells, incubated with puriﬁed HIV- and
control pEV-aliquots and analyzed for ADAM17/Rab colocalization. Analysis and quantiﬁcation (bar diagram) of the phenotype (ADAM17/Rab co-localization) as in Fig. 2.
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associated proTNF. The protease was then internalized into
endosomal compartments cleaving the intracellular TNF pool (see
cartoon Fig. 4c).3.5. Expression of Nef, TNF and Notch1 Correlate in Lymph Node Tissue
To testwhetherNef-induced TNF secretion can be observed in tissue,
we analyzed two kryo-preserved lymph nodes from a non-viremic HIV-
Fig. 4. ProTNF cleavage in Rab4+ EE is induced by the recruitment of ADAM17. (a) TNF and ADAM17 colocalize in Rab4+ compartments after Nef/NAKC expression. ADAM17, TNF-RFP
and Rab4-GFP were cotransfected w/wo Nef/NAKC. After 24 h cells were stained for ADAM17 and analyzed for ADAM17/TNF/Rab4 colocalization by confocal microscopy. Analysis and
quantiﬁcation (bar diagram) of the phenotype (ADAM17/Rab/TNF co-localization) as in Fig. 2. (b) Nef mutants abolish TNF secretion and ADAM17 trafﬁcking. Nef mutants Nef.LL/AA
and Nef.ED/AA were co-transfected with Rab-GFP proteins, TNF-RFP and NAKC and subsequently analyzed for TNF/Rap colocalization (upper two panels). Nef.LL/AA and Nef.ED/AA
were cotransfected with NAKC and ADAM17-RFP (instead of TNF-RFP; lower panels). Analysis and quantiﬁcation of the phenotype (TNF/Rab and ADAM17/Rab co-localization) as in
Fig. 2. (c) ProTNF is cleaved in two different subcellular compartments. G-pTNF-R transfected 293T cells were stimulated with PMA for indicated time intervals and analyzed by
confocal microscopy.
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sue served as control. For this analysis we used the multi-epitope-li-
gand-cartography (MELC) technology (Schubert et al., 2006), allowing
the staining of single tissue sections with multiple antibodies.
The lymph node of the HIV patient was negative for Gag p24 (data
not shown) but revealed a distinct presence of Nef that co-localized
with an increased TNF expression (Fig. 5a). TNF was secreted in large
vesicular structures and was seemingly transferred to bystander cells,
as judged by the overall speckled TNF staining pattern and budding
membrane structures (Fig. 5a, lower panels, Fig. 5d middle panel,
white arrows). The lymph node also revealed a lower and speckled ex-
pression of HLA class I, HLA DR, CD107a and CD4, and a higher expres-
sion of ADAM10 (Fig. 5b). Although, these latter signals were not
restricted to Nef-containing cells, they were consistent with an in-
creased secretion activity in this tissue.
Interestingly, we noted a strong appearance of Notch1 (Fig. 5b),
which is a substrate of ADAM17/10. Notch1 appearance correlated
with Nef and TNF staining patterns (Fig. 5c and d) and decreased radial-
ly aroundNef-expressing cells (Fig. 5c). This suggested a connection be-
tween Nef, Notch signaling and TNF secretion.
3.6. Notch1 Is Required for Nef-mediated Endocytosis of ADAM17
In lymph-node cells Notch1 appeared to have a cytoplasmic localiza-
tion (Fig. 5d). In line with this result, expression of Nef/NAKC in 293T
cells induced a cytoplasmic colocalization of Nef and endogenous
Notch1 (Fig. 6a). A nuclear translocation of the Notch1 intracellular do-
main as a consequence of this interaction seemed unlikely, as the tran-
scriptional effect of Nef/NAKC-expression on a Notch1-responsiveFig. 5. Colocalization of Nef, TNF and Notch1 in lymphnode tissue. (a) Costaining of Nef, TNF and
individual. The white arrow (bottom left panel) depicts the speckled TNF staining pattern sugge
reveal different staining patterns and expression levels of antigens. All panels show the sa
Propidiumiodid (PI). (c, d) TNF, Notch1 and Nef colocalize in cells with budding membrane str(CSL)4-luc reporter plasmid was marginal (Fig. S5a). Thus we assumed
a role of Notch1 in endocytosis and trafﬁcking.
We blocked Notch1 signaling byDibenzazepine (YO-01027) and an-
alyzed PMA- and Nef-induced cleavage of the G-pTNF-R indicator plas-
mid. Consistent with our assumption, Dibenzazepine blocked mainly
cleavage of the intracellular pool of proTNF in Nef-transfected, PMA-
stimulated (Fig. 6b) or plasmid-injected primary macrophages (Fig.
S6). This implied that ADAM17 did not reach proTNF containing
endosomes under these conditions. This was conﬁrmed when
ADAM17 trafﬁcking was studied under Dibenzazipine treatment or
Notch1 siRNA-mediated knock down: under either condition, Nef-acti-
vated ADAM17 was not internalized/routed into CCV, EE or Rab27a/b
compartments (Fig. 6c). Together this suggested that Notch1 was re-
quired for the trafﬁcking of activated ADAM17.
We reasoned that HIV-induced TNF secretion was relevant for repli-
cation in non-stimulated/resting PBMC. We infected non-stimulated
PBMCs with a wild type and a Nef-deleted virus. The infection induced
TNF-release after 6 h in both cases. However, more TNF was secreted
when Nef was present (Fig. 6d). This depended on ADAM17, as the
ADAM inhibitor TAPI blocked the cytokine release. In addition, inhibi-
tion of Notch1 reduced TNF release signiﬁcantly. For further conﬁrma-
tion non-stimulated PBMC were infected with two different infectious
doses ofwt andΔNef HIV (10 and100 ngp24) and replicationwasmea-
sured (reverse transcriptase) over 2 weeks. In this setting both virus
variants did not show a signiﬁcant difference in replication. However,
in the presence of the Notch1 inhibitor viral replication was markedly
reduced and lagged 5–10-fold behind untreated cultures in the ﬁrst
12 days. Collectively this conﬁrmed an important role for Notch1 in
the HIV life cycle.CD45 in healthy tonsil tissue and a lymphnode obtained from a non-viremic HIV-infected
sting vesicular TNF secretion. (b) MELC analysis of the HIV lymph node and healthy tonsil
me section of tonsil or lymph node tissue, stained with nine different antibodies and
uctures (white arrows in (d)).
Fig. 6. Notch1 is required for ADAM17 trafﬁcking into Rab4+ EE and proTNF cleavage. (a) Nef and Notch1 colocalize after NAKC coexpression. Nef-GFP and NAKC were transfected into
293T cells and analyzed for Nef colocalization with endogenous Notch1. (b) The Notch1 inhibitor YO-01027 blocks proTNF cleavage in primary macrophages. G-pTNF-R transfected
macrophages were co-transfected with Nef/NAKC (N) or stimulated with PMA in the presence or absence of YO-01027 as indicated. The bar diagram represents the relative
percentage of yellow and red vesicles per cell similar as described for Fig. 1. Error bars indicate standard deviation of the mean of 10 cells. (c) Inhibition of Notch1 blocks ADAM17
trafﬁcking. Rab-GFP/RFP-ADAM17/ Nef/NAKC-transfected cells were co-transfected with Notch1 siRNA or scrambled siRNA or incubated with YO-01027 as indicated and analyzed for
Rab/ADAM17 co-localization. Analysis and quantiﬁcation (bar diagram) of the phenotype (ADAM17/Rab co-localization) as in Fig. 2. (d) Nef-augmented TNF-release from infected
PBMC is blocked by TAPI and YO-01027. Resting PBMC (1 × 105) were incubated with 10 ng p24+ infectious inoculum of a nef+ (wt) or nef− (ΔNef) HIV virus for 12 h before TNF
was measured in the culture supernatant by CBA. Aliquots of the wt cultures were treated with TAPI or YO-01027 as indicated. (e) The Notch1 inhibitor YO-01027 delays HIV
replication in PBMC. Non-stimulated PBMC (2 × 106) were infected with 10 or 100 ng p24+ infectious inoculum of a wt and a nef-negative (ΔNef) HIV infectious clone and reverse
transcriptase activity was measured over 16 days as indicated. Aliquots of the cultures were treated with the Notch1 inhibitor YO-01027.
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The here presented results describe the mechanism of HIV-induced
TNF secretion in host and bystander cells. This mechanismwas induced
by Nef expression or ingestion of HIV-pEV and activated a vesicular se-
cretion type. Our work implies that HIV directly stimulates cytokine re-
lease in acute and chronic non-viremic infection.
We have previously demonstrated a transfer of Nef and Nef-associ-
ated signalingmechanisms to bystander cells bymeans of vesicle trans-
fer and trogocytosis (Muratori et al., 2009). We speculated that this
transfer of infected cell signaling (TOS) serves to prepare/activate the
resting bystander cell for viral infection. The here described vesicular se-
cretion of TNF appears to be part of this function. This type of secretion is
mechanistically different from TNF surface shedding as cleaved TNF is
kept in the lumen of endosomal vesicles (see Fig. 1d). This excludes a
surface to surface interaction, e.g. vesicle to plasma membrane, for
TNF receptor stimulation. Hence, this secretion type, which we detailed
with electronmicrographs in our previous work (Muratori et al., 2009),
is different frommicrovesicle (Cocucci et al., 2009) and Exosome release
(Thery et al., 2002) and may be termed endosomal or vesicular
secretion.
Based on our confocal analysis we suggest that pEV are endocytosed
by target cells, possibly in a clathrin-dependent manner. Subsequently
theymay fusewith endosomes, for example containing inward directed
TNF receptor molecules for sustained signaling. Although this is specu-
lation and requires further analysis, we summarized these events in a
model, which includes ﬁndings from our previous work and the litera-
ture (Fig. S7) (Muratori et al., 2009; Gonzalez-Gaitan, 2003; Lee et al.,
2013).
ADAM17 needed to be internalized into Rab4+ positive EE, in order
to converge with its substrate proTNF. This routingwas initiated by Nef,
most likely through its well described induction of clathrin coated ves-
icles (CCV) (Mangasarian et al., 1997). The CCV probably transformed
into, or fused with, pre-existing Rab4+ and proTNF-containing com-
partments. These events suggested a spatially separated TNF secretion
mechanism, which is not necessarily connected to TNF surface shed-
ding. We speculate that activation stimuli that include internalization
signals for ADAM17 (e.g. Nef or PMA) will induce endosomal proTNF
cleavage and secretion, whereas signals conﬁned to the plasma mem-
brane will cause primarily TNF shedding from the cell surface.
We found that Nef associationwith signalingmolecules (NAKC)was
required for endosomal TNF processing, suggesting that Nef-induced
endocytosis and Nef signaling serve a common purpose. This function
is characterized by two tightly linked steps. First, ADAM17 is activated
by a Nef-induced signaling process (Percario et al., 2015; Lee et al.,
2013) and, in a second step, shuttled to the proTNF pool in Rab4+ EE.
In host cells this is initiated by Nef expression, in bystander cells via
Nef EV-ingestion. By whichmechanism incoming Nef pEV induce inter-
nalization of cell-resident ADAM17 (as in Fig. 3) is not clear. Based on
our data we could envision a scenario by which incoming pEV fuse
with endosomes containing cellular ADAM17 (Fig. S7).
Our in vitro ﬁndings were conﬁrmed by the MELC analysis of two
lymph nodes. The latter conﬁrmed a predominantly vesicular secretion
mechanism for TNF. In addition the analysis suggested a role of Notch1
in TNF secretion. For its activation Notch1 requires the processing by
ADAM proteases (Musse et al., 2012) and thus could be a downstream
effector of Nef. Notch function is usually linked to the nuclear transloca-
tion of its intracellular domain (NICD) (Baron, 2012). However, we
could not conﬁrm a transcriptional effect of Nef/NAKC via Notch1. A li-
gand-independent role of Notch1 is now recognized in endosomal traf-
ﬁcking (Palmer and Deng, 2015), shuttling surface proteins into
endosomal compartments (Waters et al., 2012). Furthermore, the pro-
tein was found to be required for cytokine secretion in T cells (Benson
et al., 2005; Manaster et al., 2010). Thus the receptor could have a role
in ADAM17 trafﬁcking. Our results are seemingly in contrast to a previ-
ous ﬁnding in a mouse model, describing HIV-mediated transcriptionalactivation of Notch1 and 4 in kidney cells (Sharma et al., 2010). Poten-
tially HIV-activated Notch1 has cell-type dependent transcriptional
effects.
The here proposedNef function raises the question ofwhy the rather
complex generation of ADAM17-containing EV evolved over a direct
stimulation of transcription?We speculate that HIV-pEV induce a radial
perpetuation of TNF secretion around infected cells leading to bystander
cell activation. In fact, early dissemination of the virus in vaginal tissue
(SIV) occurs in such a radial manner (Li et al., 2005). This conclusion is
also supported by our observations in tissue, demonstrating the pres-
ence of TNF and also Notch1 in a seemingly radial gradient fromNef-ex-
pressing cells. Potentially, pEV-associated TNF is particularly potent.
Since TNF has to bind TNF receptors as a trimer, this requires higher con-
centrations of the cytokine, which are easier achieved in closed
endosomal compartments, rather than the extracellular space. Taken
together a strong pEV-mediated TNF secretion and stimulation mecha-
nismmay induce an efﬁcient radial transmission of HIV into resting host
cells.
Nef-containing HIV-pEV and the Nef-expressing lymph nodes imply
persistent transcription of at least some viral proteins under ART, that
may even occur without viral integration (Kelly et al., 2008). Irrespec-
tive of the speciﬁc mechanism involved, our ﬁndings challenge the cur-
rently prevailing view that effective ART almost fully suppresses virus
replication and protein production. In support of such activity under
ART, reports based on different experimental approaches are beginning
to emerge that hint at the existence of viral sanctuaries in chronic HIV
infection in which virus replication can occur (North et al., 2010;
Fukazawa et al., 2015; Lorenzo-Redondo et al., 2016; Lee et al., 2016;
Kumar et al., 2016). Identifying these tissue sanctuaries will be of
great importance for the treatment of chronic HIV infection.
Conﬂict of Interest
The authors declare no conﬂict of interest.
Funding Sources
S.W., JH.L. and A.S.B. were supported by the German Research Foun-
dation (DFG; BA961/4-1) including the Collaborative Research Center
grant SFB 643 (Project A9) and by funds from the European Union
(HIVERA IRIFCURE). C.O. is supported by the Comprehensive Cancer
Center (CCC) Erlangen. T.H. was supported by the Emerging Fields Pro-
gramof the Friedrich-Alexander-University of Erlangen-Nürnberg. O.T.F
acknowledges funding from the Deutsche Forschungsgemeinschaft
(TRR83 project 15) and the European Union (HIVERA IRIFCURE).
Author Contributions
The project was conceptualized and coordinated by A.S.B. Substan-
tial contributions to the work were made by C.O. (MELC analysis, trans-
fections, immunoﬂuorescence); S.W. (transfections, confocal imaging);
JH.L. (Western Blot); MM.G. (microinjection experiments); N.T. (HIV
replication assay); T.H. (plasma and tissue sample analysis); O.F. and
G.S. (expertise, feedback and reagents).
Acknowledgement
The anti-Nef antibodies were a generous gift from NEXT Biomed in
Helsinki.
Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.ebiom.2016.10.027.
304 C. Ostalecki et al. / EBioMedicine 13 (2016) 294–304References
Abraham, L., Fackler, O.T., 2012. HIV-1 Nef: a multifaceted modulator of T cell receptor
signaling. Cell Commun. Signal 10, 39.
Aukrust, P., Muller, F., Lien, E., Nordoy, I., Liabakk, N.B., Kvale, D., Espevik, T., Froland, S.S.,
1999. Tumor necrosis factor (TNF) system levels in human immunodeﬁciency virus-
infected patients during highly active antiretroviral therapy: persistent TNF activa-
tion is associated with virologic and immunologic treatment failure. J. Infect. Dis.
179, 74–82.
Baron, M., 2012. Endocytic routes to Notch activation. Semin. Cell Dev. Biol. 23, 437–442.
Baur, A.S., 2011. HIV-Nef and AIDS pathogenesis: are we barking up the wrong tree?
Trends Microbiol. 19, 435–440.
Baur, A.S., Lutz, M.B., Schierer, S., Beltrame, L., Theiner, G., Zinser, E., Ostalecki, C.,
Heidkamp, G., Haendle, I., Erdmann, M., Wiesinger, M., Leisgang, W., Gross, S.,
Pommer, A.J., Kampgen, E., Dudziak, D., Steinkasserer, A., Cavalieri, D., Schuler-
Thurner, B., Schuler, G., 2013. Denileukin diftitox (ONTAK) induces a tolerogenic phe-
notype in dendritic cells and stimulates survival of resting Treg. Blood 122,
2185–2194.
Benson, R.A., Adamson, K., Corsin-Jimenez, M., Marley, J.V., Wahl, K.A., Lamb, J.R., Howie,
S.E., 2005. Notch1 co-localizes with CD4 on activated T cells and Notch signaling is re-
quired for IL-10 production. Eur. J. Immunol. 35, 859–869.
Bresnahan, P.A., Yonemoto, W., Ferrell, S., Williams-Herman, D., Geleziunas, R., Greene,
W.C., 1998. A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4
downregulation and binds the AP-1 clathrin adaptor. Curr. Biol. 8, 1235–1238.
Chaudhry, A., Das, S.R., Jameel, S., George, A., Bal, V., Mayor, S., Rath, S., 2008. HIV-1 Nef
induces a Rab11-dependent routing of endocytosed immune costimulatory proteins
CD80 and CD86 to the Golgi. Trafﬁc 9, 1925–1935.
Cocucci, E., Racchetti, G., Meldolesi, J., 2009. Shedding microvesicles: artefacts no more.
Trends Cell Biol. 19.
Fackler, O.T., Moris, A., Tibroni, N., Giese, S.I., Glass, B., Schwartz, O., Krausslich, H.G., 2006.
Functional characterization of HIV-1 Nef mutants in the context of viral infection. Vi-
rology 351, 322–339.
Fauci, A.S., 1996. Host factors and the pathogenesis of HIV-induced disease. Nature 384,
529–534.
Fukazawa, Y., Lum, R., Okoye, A.A., Park, H., Matsuda, K., Bae, J.Y., Hagen, S.I., Shoemaker,
R., Deleage, C., Lucero, C., Morcock, D., Swanson, T., Legasse, A.W., Axthelm, M.K.,
Hesselgesser, J., Geleziunas, R., Hirsch, V.M., Edlefsen, P.T., Piatak Jr., M., Estes, J.D.,
Lifson, J.D., Picker, L.J., 2015. B cell follicle sanctuary permits persistent productive
simian immunodeﬁciency virus infection in elite controllers. Nat. Med. 21, 132–139.
Gallitano, S.M., McDermott, L., Brar, K., Lowenstein, E., 2016. Use of tumor necrosis factor
(TNF) inhibitors in patients with HIV/AIDS. J. Am. Acad. Dermatol. 74, 974–980.
Gonzalez-Gaitan, M., 2003. Signal dispersal and transduction through the endocytic path-
way. Nat. Rev. Mol. Cell Biol. 4, 213–224.
Gorry, P.R., McPhee, D.A., Verity, E., Dyer, W.B., Wesselingh, S.L., Learmont, J., Sullivan, J.S.,
Roche, M., Zaunders, J.J., Gabuzda, D., Crowe, S.M., Mills, J., Lewin, S.R., Brew, B.J.,
Cunningham, A.L., Churchill, M.J., 2007. Pathogenicity and immunogenicity of attenu-
ated, nef-deleted HIV-1 strains in vivo. Retrovirology 4, 66.
Iwasaki, A., 2012. Innate immune recognition of HIV-1. Immunity 37, 389–398.
Kelly, J., Beddall, M.H., Yu, D., Iyer, S.R., Marsh, J.W., Wu, Y., 2008. Human macrophages
support persistent transcription from unintegrated HIV-1 DNA. Virology 372,
300–312.
Kumar, A., Abbas, W., Herbein, G., 2013. TNF and TNF receptor superfamily members in
HIV infection: new cellular targets for therapy? Mediat. Inﬂamm. 2013, 484378.
Kumar, A., Abbas,W., Colin, L., Khan, K.A., Bouchat, S., Varin, A., Larbi, A., Gatot, J.S., Kabeya,
K., Vanhulle, C., Delacourt, N., Pasquereau, S., Coquard, L., Borch, A., Konig, R.,
Clumeck, N., De, W.S., Rohr, O., Rouzioux, C., Fulop, T., Van, L.C., Herbein, G., 2016.
Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in lim-
ited recovery in latently HIV infected T-cell line. Sci. Rep. 6, 24090.
Lawn, S.D., 2004. AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1
infection. J. Infect. 48, 1–12.
Lee, J.H., Wittki, S., Brau, T., Dreyer, F.S., Kratzel, K., Dindorf, J., Johnston, I.C., Gross, S.,
Kremmer, E., Zeidler, R., Schlotzer-Schrehardt, U., Lichtenheld, M., Saksela, K.,
Harrer, T., Schuler, G., Federico, M., Baur, A.S., 2013. HIV Nef, paxillin, and Pak1/2 reg-
ulate activation and secretion of TACE/ADAM10 proteases. Mol. Cell 49, 668–679.
Lee, J.H., Schierer, S., Blume, K., Dindorf, J., Wittki, S., Xiang, W., Ostalecki, C., Koliha, N.,
Wild, S., Schuler, G., Fackler, O.T., Saksela, K., Harrer, T., Baur, A.S., 2016. HIV-Nef
and ADAM17-containing plasma extracellular vesicles induce and correlate with im-
mune pathogenesis in chronic HIV infection. EBioMedicine 6, 103–113.
Li, Q., Duan, L., Estes, J.D., Ma, Z.M., Rourke, T., Wang, Y., Reilly, C., Carlis, J., Miller, C.J.,
Haase, A.T., 2005. Peak SIV replication in resting memory CD4+ T cells depletes gut
lamina propria CD4+ T cells. Nature 434, 1148–1152.
Lorenzo-Redondo, R., Fryer, H.R., Bedford, T., Kim, E.Y., Archer, J., Kosakovsky Pond, S.L.,
Chung, Y.S., Penugonda, S., Chipman, J.G., Fletcher, C.V., Schacker, T.W., Malim, M.H.,
Rambaut, A., Haase, A.T., McLean, A.R., Wolinsky, S.M., 2016. Persistent HIV-1 replica-
tion maintains the tissue reservoir during therapy. Nature 530, 51–56.Lu, X., Yu, H., Liu, S.H., Brodsky, F.M., Peterlin, B.M., 1998. Interactions between HIV1 Nef
and vacuolar ATPase facilitate the internalization of CD4. Immunity 8, 647–656.
Madrid, R., Janvier, K., Hitchin, D., Day, J., Coleman, S., Noviello, C., Bouchet, J., Benmerah,
A., Guatelli, J., Benichou, S., 2005. Nef-induced alteration of the early/recycling
endosomal compartment correlates with enhancement of HIV-1 infectivity. J. Biol.
Chem. 280, 5032–5044.
Manaster, I., Gazit, R., Goldman-Wohl, D., Stern-Ginossar, N., Mizrahi, S., Yagel, S.,
Mandelboim, O., 2010. Notch activation enhances IFNgamma secretion by human pe-
ripheral blood and decidual NK cells. J. Reprod. Immunol. 84, 1–7.
Mangasarian, A., Foti, M., Aiken, C., Chin, D., Carpentier, J.L., Trono, D., 1997. The HIV-1 Nef
protein acts as a connector with sorting pathways in the Golgi and at the plasma
membrane. Immunity 6, 67–77.
Muratori, C., Cavallin, L.E., Kratzel, K., Tinari, A., De, M.A., Fais, S., D'Aloja, P., Federico, M.,
Vullo, V., Fomina, A., Mesri, E.A., Superti, F., Baur, A.S., 2009. Massive secretion by T
cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells.
Cell Host Microbe 6, 218–230.
Musse, A.A., Meloty-Kapella, L., Weinmaster, G., 2012. Notch ligand endocytosis: mecha-
nistic basis of signaling activity. Semin. Cell Dev. Biol. 23, 429–436.
North, T.W., Higgins, J., Deere, J.D., Hayes, T.L., Villalobos, A., Adamson, L., Shacklett, B.L.,
Schinazi, R.F., Luciw, P.A., 2010. Viral sanctuaries during highly active antiretroviral
therapy in a nonhuman primate model for AIDS. J. Virol. 84, 2913–2922.
Palmer, W.H., Deng, W.M., 2015. Ligand-independent mechanisms of Notch activity.
Trends Cell Biol. 25, 697–707.
Percario, Z.A., Ali, M., Mangino, G., Affabris, E., 2015. Nef, the shuttling molecular adaptor
of HIV, inﬂuences the cytokine network. Cytokine Growth Factor Rev. 26, 159–173.
Reddy, M.M., Sorrell, S.J., Lange, M., Grieco, M.H., 1988. Tumor necrosis factor and HIV P24
antigen levels in serum of HIV-infected populations. J. Acquir. Immune Deﬁc. Syndr.
1, 436–440.
Sampey, G.C., Saifuddin, M., Schwab, A., Barclay, R., Punya, S., Chung, M.C., Hakami, R.M.,
Zadeh, M.A., Lepene, B., Klase, Z.A., El-Hage, N., Young, M., Iordanskiy, S., Kashanchi,
F., 2016. Exosomes from HIV-1-infected cells stimulate production of pro-inﬂamma-
tory cytokines through trans-activating response (TAR) RNA. J. Biol. Chem. 291,
1251–1266.
Sandler, N.G., Douek, D.C., 2012. Microbial translocation in HIV infection: causes, conse-
quences and treatment opportunities. Nat. Rev. Microbiol. 10, 655–666.
Schaefer, M.R., Wonderlich, E.R., Roeth, J.F., Leonard, J.A., Collins, K.L., 2008. HIV-1 Nef tar-
gets MHC-I and CD4 for degradation via a ﬁnal common beta-COP-dependent path-
way in T cells. PLoS Pathog. 4, e1000131.
Schmidt, S., Fritz, J.V., Bitzegeio, J., Fackler, O.T., Keppler, O.T., 2011. HIV-1 Vpu blocks
recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin
to overcome the virion release restriction. MBio 2 (e00036-11).
Schubert, W., Bonnekoh, B., Pommer, A.J., Philipsen, L., Bockelmann, R., Malykh, Y.,
Gollnick, H., Friedenberger, M., Bode, M., Dress, A.W., 2006. Analyzing proteome to-
pology and function by automated multidimensional ﬂuorescence microscopy. Nat.
Biotechnol. 24, 1270–1278.
Sharma, M., Callen, S., Zhang, D., Singhal, P.C., Vanden Heuvel, G.B., Buch, S., 2010. Activa-
tion of Notch signaling pathway in HIV-associated nephropathy. AIDS 24, 2161–2170.
Stenmark, H., 2009. Rab GTPases as coordinators of vesicle trafﬁc. Nat. Rev. Mol. Cell Biol.
10, 513–525.
Stow, J.L., Murray, R.Z., 2013. Intracellular trafﬁcking and secretion of inﬂammatory cyto-
kines. Cytokine Growth Factor Rev. 24, 227–239.
Thery, C., Zitvogel, L., Amigorena, S., 2002. Exosomes: composition, biogenesis and func-
tion. Nat. Rev. Immunol. 2.
Trotard, M., Tsopoulidis, N., Tibroni, N., Willemsen, J., Binder, M., Ruggieri, A., Fackler, O.T.,
2016. Sensing of HIV-1 infection in Tzm-bl cells with reconstituted expression of
STING. J. Virol. 90, 2064–2076.
Wada, N.I., Jacobson, L.P., Margolick, J.B., Breen, E.C., Macatangay, B., Penugonda, S.,
Martinez-Maza, O., Bream, J.H., 2015. The effect of HAART-induced HIV suppression
on circulating markers of inﬂammation and immune activation. AIDS 29, 463–471.
Waters, A.M., Wu, M.Y., Huang, Y.W., Liu, G.Y., Holmyard, D., Onay, T., Jones, N., Egan, S.E.,
Robinson, L.A., Piscione, T.D., 2012. Notch promotes dynamin-dependent endocytosis
of nephrin. J. Am. Soc. Nephrol. 23, 27–35.
Witte, V., Laffert, B., Rosorius, O., Lischka, P., Blume, K., Galler, G., Stilper, A., Willbold, D.,
D'Aloja, P., Sixt, M., Kolanus, J., Ott, M., Kolanus, W., Schuler, G., Baur, A.S., 2004.
HIV-1 Nef mimics an integrin receptor signal that recruits the polycomb group pro-
tein Eed to the plasma membrane. Mol. Cell 13, 179–190.
Wolf, D., Witte, V., Laffert, B., Blume, K., Stromer, E., Trapp, S., D'Aloja, P., Schurmann, A.,
Baur, A.S., 2001. HIV-1 Nef associated PAK and PI3-kinases stimulate Akt-indepen-
dent Bad-phosphorylation to induce anti-apoptotic signals. Nat. Med. 7, 1217–1224.
Wolf, D., Witte, V., Clark, P., Blume, K., Lichtenheld, M.G., Baur, A.S., 2008. HIV Nef en-
hances Tat-mediated viral transcription through a hnRNP-K-nucleated signaling
complex. Cell Host Microbe 4, 398–408.
